Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 1
2002 3
2004 5
2005 5
2006 6
2007 4
2008 1
2009 3
2010 10
2011 12
2012 15
2013 7
2014 7
2015 15
2016 12
2017 11
2018 8
2019 20
2020 15
2021 17
2022 8
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

160 results
Results by year
Filters applied: . Clear all
Page 1
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Rothschild SI, et al. Among authors: joerger m. J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12. J Clin Oncol. 2021. PMID: 34251873 Free article. Clinical Trial.
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind FG, Ellinger J, Brossart P, Diem S, Schmid S, Joerger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. Klümper N, et al. Among authors: joerger m. J Immunother Cancer. 2022 Mar;10(3):e004024. doi: 10.1136/jitc-2021-004024. J Immunother Cancer. 2022. PMID: 35292517 Free PMC article.
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Abdou MT, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng HW, Toma M, Klümper N, Purde MT, Pop OT, Jochum AK, Pascolo S, Joerger M, Früh M, Jochum W, Rammensee HG, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Berner F, et al. Among authors: joerger m. Sci Immunol. 2022 Sep 2;7(75):eabn9644. doi: 10.1126/sciimmunol.abn9644. Epub 2022 Sep 2. Sci Immunol. 2022. PMID: 36054337
Radiotherapy for thymic epithelial tumours: a review.
Süveg K, Putora PM, Joerger M, Iseli T, Fischer GF, Ammann K, Glatzer M. Süveg K, et al. Among authors: joerger m. Transl Lung Cancer Res. 2021 Apr;10(4):2088-2100. doi: 10.21037/tlcr-20-458. Transl Lung Cancer Res. 2021. PMID: 34012817 Free PMC article. Review.
Dose-toxicity models in oncology.
Adamina M, Joerger M. Adamina M, et al. Among authors: joerger m. Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):201-11. doi: 10.1517/17425255.2011.543674. Expert Opin Drug Metab Toxicol. 2011. PMID: 21241201 Review.
Metabolism of the taxanes including nab-paclitaxel.
Joerger M. Joerger M. Expert Opin Drug Metab Toxicol. 2015 May;11(5):691-702. doi: 10.1517/17425255.2015.983074. Epub 2014 Nov 14. Expert Opin Drug Metab Toxicol. 2015. PMID: 25394848 Review.
Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Boesch M, Baty F, Rothschild SI, Tamm M, Joerger M, Früh M, Brutsche MH. Boesch M, et al. Among authors: joerger m. Br J Cancer. 2021 Aug;125(3):313-323. doi: 10.1038/s41416-021-01365-2. Epub 2021 Apr 6. Br J Cancer. 2021. PMID: 33824481 Free PMC article. Review.
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Nuñez NG, et al. Among authors: joerger m. Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381 Free article.
Role of TDM-based dose adjustments for taxane anticancer drugs.
Muth M, Ojara FW, Kloft C, Joerger M. Muth M, et al. Among authors: joerger m. Br J Clin Pharmacol. 2021 Feb;87(2):306-316. doi: 10.1111/bcp.14678. Epub 2020 Dec 18. Br J Clin Pharmacol. 2021. PMID: 33247980 Free article. Review.
160 results